NVS Novartis AG
- 97.270
- -0.070-0.07%
- 96.470
- -0.800-0.82%
Novartis AG News
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal
Sector Update: Health Care Stocks Retreat Thursday Afternoon
Health care stocks were declining Thursday afternoon, with the NYSE Health Care Index shedding 0.6% and the Health Care Select Sector SPDR Fund (XLV) down 0.2%. The iShares Biotechnology ETF (IBB) ros
Novartis to Pay up to $1.75 Billion for U.S. Cancer-focused Biotech
By Steve Goldstein Pharmaceutical giant Novartis AG on Thursday said it will pay up to $1.75 billion for a U.S. biotech focused on cancer. Novartis said it's paying $1 billion upfront and up to $750
Novartis to Pay $1B Upfront for Mariana, Additional $750M Upon Completion of Milestones
Novartis to Pay $1B Upfront for Mariana, Additional $750M Upon Completion of Milestones
Express News | Market news: Novartis will buy radiopharmaceuticals company Mariana Oncology with a $1 billion upfront payment.
Novartis: Mariana Oncology Is U.S.Biotechnology Company Focused on Developing Treatments for Cancers With High Unmet Need
Novartis: Mariana Oncology Is U.S.Biotechnology Company Focused on Developing Treatments for Cancers With High Unmet Need
Novartis: Acquisition Aimed at Improving Radioligand Therapy Pipeline
Novartis: Acquisition Aimed at Improving Radioligand Therapy Pipeline
Novartis Enters Agreement to Acquire Mariana Oncology
Novartis Enters Agreement to Acquire Mariana Oncology
CVS Stresses 'Margins Over Membership' to Offset Medicare Pressure
Novartis Is Tracking Well Above the Industry
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
The Federal Trade Commission (FTC) announced Tuesday that it sent warning letters to 10 companies and notified the Food and Drug Administration (FDA) that it disputes the accuracy or relevance of more
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
PeptiDream Announces Expansion of Peptide Discovery Collaboration With Novartis
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter "PeptiDream") (TYO:4587) today announced an expansion of its peptide discovery collaboration
Terns Pharmaceuticals Releases Promising Phase 1 Data on Leukemia Candidate
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
MorphoSys AG (NASDAQ:MOR) is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment.Myelofibrosis is a type of blood cancer characterized by the
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Impacted by reports of drug safety issues, Morphosys (MOR.US) says the Novartis Pharmaceuticals (NVS.US) acquisition will continue as planned
The Zhitong Finance App learned that on Monday, the stock price of German biotech company Morphosys (MOR.US) fell due to a news report about its drugs or safety risks, but Morphosys said that Novartis Pharmaceuticals (NVS.US) is still expected to complete its acquisition in the first half of this year. Prior to Morphosys' statement, the professional website StatNews quoted two people familiar with the matter as reporting that the company is developing an experimental drug pelabresib to treat myelofibrosis (a rare type of blood cancer affecting bone marrow)
New Safety Risk for MorphoSys Drug Could Complicate Novartis Deal - STAT
A new safety risk related to Morphosys's (NASDAQ:MOR) pelabresib, an experimental treatment for myelofibrosis, could complicate the company's planned $3B sale to Novartis (NYSE:NVS).
J&J, Roche, AstraZeneca Poised to Have Highest Orphan Drug Sales by End of Decade
Analysis
Price Target
No Data
